Findings presented at European Society for Medical Oncology include models in solid tumors and hematologic malignanciesSOUTH ...
Pregnancy and breastfeeding induces the accumulation of specialized immune cells that reduce the chances of breast cancer ...
Some 68% of patients with autoimmune disease had "major" side effects from CAR-T therapy for myeloma, lymphoma, or leukemia, ...
Researchers from the Alliance for Clinical Trials in Oncology have found that two targeted immunotherapy drugs lead to high ...
Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the ...
Researchers from Rutgers Health and other institutions have discovered why a powerful leukemia drug eventually fails in most ...
IDH1 inhibitors show strong efficacy and tolerability in IDH1-mutated AML and MDS, with some patients achieving long-term ...
Cellectis SA ( ($CLLS) ) has provided an announcement. On October 16, 2025, Cellectis S.A. hosted an Investors R&D Day, unveiling promising data ...
Samer A. Srour, MB ChB, MS, has long hoped the remarkable success of chimeric antigen receptor therapy for treatment of hematologic malignancies could be replicated in other cancer types.“There is a ...